Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is anticipated to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Lantern Pharma to post earnings of ($0.46) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Lantern Pharma Price Performance

LTRN opened at $2.87 on Thursday. The stock has a market capitalization of $32.09 million, a P/E ratio of -1.64 and a beta of 1.55. The company’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.68. Lantern Pharma has a one year low of $2.45 and a one year high of $5.74.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LTRN. Cetera Investment Advisers acquired a new position in Lantern Pharma in the fourth quarter valued at about $37,000. XTX Topco Ltd bought a new stake in shares of Lantern Pharma in the 2nd quarter valued at about $40,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Lantern Pharma in the 4th quarter valued at approximately $47,000. Two Sigma Investments LP bought a new position in Lantern Pharma during the 3rd quarter worth approximately $70,000. Finally, Susquehanna International Group LLP bought a new position in Lantern Pharma during the 3rd quarter worth approximately $170,000. 28.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wall Street Zen upgraded Lantern Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lantern Pharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $25.00.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.